OPEN-LABEL STUDY OF PEGPH20 WITH CIS AND GEM; PEGPH20 WITH ATEZOLIZUMAB, CIS AND GEM; AND COMPARED WITH CIS AND GEM ALONE IN HA-HIGH SUBJECTS WITH PREVIOUSLY UNTREATED, UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC INTRAHEPATIC AND EXTRAHEPATIC CHOLANGIOCARCINOMA AND GALLBLADDER ADENOCARCINOMA: